PREVDUO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prevduo, and when can generic versions of Prevduo launch?
Prevduo is a drug marketed by Azurity and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in PREVDUO is glycopyrrolate; neostigmine methylsulfate. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the glycopyrrolate; neostigmine methylsulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Prevduo
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 25, 2038. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PREVDUO?
- What are the global sales for PREVDUO?
- What is Average Wholesale Price for PREVDUO?
Summary for PREVDUO
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for PREVDUO |
| What excipients (inactive ingredients) are in PREVDUO? | PREVDUO excipients list |
| DailyMed Link: | PREVDUO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PREVDUO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for PREVDUO
US Patents and Regulatory Information for PREVDUO
PREVDUO is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PREVDUO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting PREVDUO
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | PREVDUO | glycopyrrolate; neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 216903-001 | Feb 23, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Azurity | PREVDUO | glycopyrrolate; neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 216903-001 | Feb 23, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Azurity | PREVDUO | glycopyrrolate; neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 216903-001 | Feb 23, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
